TLDR
- Acurx posts a lower 2025 net loss while expanding ibezapolstat trials.
- The company launches a pilot rCDI trial to position ibezapolstat for Phase 3.
- New patent extends protection for Pol IIIC inhibitors through 2039.
- 2025 R&D and G&A costs decline significantly versus the prior year.
- Ibezapolstat Phase 2 shows a 96% cure in acute CDI patients.
Acurx Pharmaceuticals, Inc. reported financial results for 2025 while advancing its ibezapolstat clinical program. The stock trades at $4.06 as of March 13, 2026. The company continues progressing toward Phase 3 trials for its lead CDI antibiotic candidate.
Acurx Pharmaceuticals, Inc., ACXP
Ibezapolstat: Clinical Advancements
Acurx launched a new clinical trial targeting multiply recurrent CDI patients. The open-label pilot will enroll patients with at least three episodes of CDI in the past 12 months. The data will inform design elements for an active-controlled Phase 3 registration trial.
The company emphasizes ibezapolstat’s microbiome-sparing properties observed in Phase 2, with a 96% cure rate and no recurrence. The goal of this trial is to make ibezapolstat the only drug that can treat and prevent rCDI. The program follows regulatory guidance from the FDA and EMA, which supports the clinical strategy.
Additionally, ibezapolstat has Fast Track and QIDP designations in the United States. Acurx is planning international Phase 3 trials with endpoints designed to demonstrate non-inferiority versus vancomycin. The Phase 3 program could support a marketing authorization application in Europe following successful completion.
Research and Scientific Milestones
In November 2025, structural biology research confirmed ibezapolstat binding to DNA pol IIIC in Gram-positive bacteria. The study strengthens the foundation for the development of this new class of antibiotics. Collaboration with Leiden University Medical Center has supported multiple preclinical advancements in this program.
A new USPTO patent granted in February 2026 covers the composition and method of use of Pol IIIC inhibitors. This patent extends through 2039, subject to extensions under US patent rules. Prior IDWeek presentations highlighted microbiome-sparing effects and preclinical data from a mouse infection model.
The company’s preclinical pipeline includes oral candidates for ABSSSI and a parallel program for inhaled anthrax. The research emphasizes selective gram-positive activity while sparing other gut microbiota. These programs align with Acurx’s strategy to address urgent bacterial threats efficiently.
Financial Performance and Capital Position
Acurx ended 2025 with $7.6 million in cash, up from $3.7 million in 2024. The increase included $1.5 million raised in Q4 under its Equity Line of Credit. Total proceeds from the equity line reached $4.0 million for the year.
R&D expenses decreased to $1.8 million for 2025, down from $5.4 million in 2024. The reduction reflects lower manufacturing and consulting costs following prior Phase 2b and Phase 3 preparations. General and administrative expenses fell to $6.3 million versus $8.7 million in 2024, mainly from reduced professional fees and share-based compensation.
Net loss narrowed to $8.0 million for the year, compared to $14.1 million in 2023. Quarterly net loss also declined to $1.6 million from $2.8 million in the same period of 2024. Acurx reported 2,348,113 shares outstanding as of December 31, 2023.
The company plans a conference call with CEO David Luci and CFO Robert Shawah to discuss financial results and business updates. We encourage investors and stakeholders to attend the call for detailed operational insights.
Acurx Pharmaceuticals remains focused on advancing ibezapolstat to Phase 3 international trials while maintaining a disciplined cost structure. With its novel DNA pol IIIC inhibitors, the company is well-positioned to tackle urgent bacterial threats.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
